Penumbra Inc

Penumbra develops and manufactures medical devices designed to address challenging vascular conditions throughout the body, operating as a single segment focused on thrombectomy, embolization, and access solutions. The company's thrombectomy portfolio includes computer-assisted vacuum aspiration systems, continuous aspiration mechanical catheters, and reperfusion devices used to treat ischemic stroke, pulmonary embolism, deep vein thrombosis, and acute limb ischemia. In addition, it produces peripheral and neurovascular embolization devices, such as detachable coils and occlusion systems, alongside guide and intermediate access catheters and neurosurgical evacuation tools. Penumbra primarily sells these products directly to healthcare providers and hospital systems for use by specialist physicians, including interventional radiologists, neuroradiologists, vascular surgeons, neurosurgeons, and interventional cardiologists.

The enterprise maintains direct commercial sales forces across the United States, Canada, Australia, Singapore, and most European nations, supplemented by independent distributors in other international territories and a licensing partner in China. It conducts research, development, and manufacturing operations in Alameda and Roseville, California.

Summary of the business section of Penumbra's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 4,700 employees worldwide.”